Thromboxane A2 promotes soluble CD40 ligand release from human platelets

Libby, 2000, Inflammation in atherosclerosis, Nature, 420, 686 Henn, 1998, CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells, Nature, 391, 591, 10.1038/35393 Davì, 2007, Platelet activation and atherothrombosis, N Engl J Med, 357, 2482, 10.1056/NEJMra071014 Furman, 2004, Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization, J Am Coll Cardiol, 43, 2319, 10.1016/j.jacc.2003.12.055 Mach, 1998, Reduction of atherosclerosis in mice by inhibition of CD40 signaling, Nature, 394, 200, 10.1038/28204 Heeschen, 2003, Soluble CD40 ligand in acute coronary syndromes, N Engl J Med, 348, 1104, 10.1056/NEJMoa022600 Garlichs, 2001, Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets, Heart, 86, 649, 10.1136/heart.86.6.649 Garlichs, 2003, Upregulation of CD40–CD40 ligand (CD154) in patients with acute cerebral ischemia, Stroke, 34, 1412, 10.1161/01.STR.0000074032.64049.47 Santilli, 2006, Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus, J Am Coll Cardiol, 47, 391, 10.1016/j.jacc.2005.03.079 Harding, 2004, Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus, Atherosclerosis, 176, 321, 10.1016/j.atherosclerosis.2004.05.008 Novo, 2005, Soluble CD40L and cardiovascular risk in asymptomatic low-grade carotid stenosis, Stroke, 36, 673, 10.1161/01.STR.0000154878.58398.14 Schönbeck, 2001, Soluble CD40L and cardiovascular risk in women, Circulation, 104, 2266, 10.1161/hc4401.099447 de Lemos, 2005, Association between soluble CD40 ligand, atherosclerotic risk factors, and subclinical atherosclerosis: results from Dallas Heart Study, Arterioscler Thromb Vasc Biol, 25, 2192, 10.1161/01.ATV.0000182904.08513.60 Nannizzi-Alaimo, 2003, Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation, Circulation, 107, 1123, 10.1161/01.CIR.0000053559.46158.AD Berndt, 2001, The vascular biology of the glycoprotein Ib–IX–V complex, Thromb Haemost, 86, 178, 10.1055/s-0037-1616216 Dong, 2001, Ristocetin-dependent, but not botrocetin-dependent, binding of von Willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with shear-dependent interactions, Blood, 97, 162, 10.1182/blood.V97.1.162 Garcia, 2005, Src family kinase-mediated and Erk-mediated thromboxane A2 generation are essential for VWF/GPIb-induced fibrinogen receptor activation in human platelets, Blood, 106, 3410, 10.1182/blood-2005-05-1933 Tamura, 2003, Shear-induced von Willebrand factor-mediated platelet surface translocation of the CD40 ligand, Thromb Res, 108, 311, 10.1016/S0049-3848(03)00098-7 Kato, 1996, Modulation of the stress-induced synthesis of hsp27 and alpha B-crystallin by cyclic AMP in C6 rat glioma cells, J Neurochem, 66, 946, 10.1046/j.1471-4159.1996.66030946.x Catella, 1986, 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation, Proc Natl Acad Sci USA, 83, 5861, 10.1073/pnas.83.16.5861 Smith, 1998, Pharmacological analysis of cyclooxygenase-1 in inflammation, Proc Natl Acad Sci USA, 95, 13313, 10.1073/pnas.95.22.13313 Naito, 1983, Effects of thromboxane synthetase inhibitors on aggregation of rabbit platelets, Eur J Pharmacol, 91, 41, 10.1016/0014-2999(83)90359-X Nicolaou, 1979, Synthesis and biological properties of pinane-thromboxane A2, a selective inhibitor of coronary artery constriction, platelet aggregation, and thromboxane formation, Proc Natl Acad Sci USA, 76, 2566, 10.1073/pnas.76.6.2566 Bertelé, 1980, U-46619, a stable analogue of prostaglandin H2, induces retraction of human platelet-rich plasma clots, Thromb Res, 18, 543, 10.1016/0049-3848(80)90350-3 Egan, 2006, Eicosanoids and the vascular endothelium, Handb Exp Pharmacol, 176, 189, 10.1007/3-540-32967-6_6 Patrignani, 1982, Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects, J Clin Invest, 69, 1366, 10.1172/JCI110576 Capone, 2004, Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects, Circulation, 109, 1468, 10.1161/01.CIR.0000124715.27937.78 Nakahata, 2008, Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology, Pharmacol Ther, 118, 18, 10.1016/j.pharmthera.2008.01.001 Cuenda, 1995, SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1, FEBS Lett, 364, 229, 10.1016/0014-5793(95)00357-F Alessi, 1995, PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo, J Biol Chem, 270, 27489, 10.1074/jbc.270.46.27489 Bennett, 2001, Anderson DW SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase, Proc Natl Acad Sci USA, 98, 13681, 10.1073/pnas.251194298 Liu, 2004, The roles of ADP and TXA2 in botorocatin/VWF-induced aggregation of washed platelets, J Thromb Haemost, 2, 2213, 10.1111/j.1538-7836.2004.01023.x Pignatelli, 2004, gp91phoz-dependent expression of platelet CD40 ligand, Circulation, 110, 1326, 10.1161/01.CIR.0000134963.77201.55 Glagov, 1987, Compensatory enlargement of human atherosclerotic coronary arteries, N Engl J Med, 316, 1371, 10.1056/NEJM198705283162204 Korshunov, 2007, Vascular remodeling: hemodynamic and biochemical mechanisms underlying Glagov's phenomenon, Arterioscler Thromb Vasc Biol, 27, 1722, 10.1161/ATVBAHA.106.129254 Malek, 1999, Hemodynamic shear stress and its role in atherosclerosis, JAMA, 282, 2035, 10.1001/jama.282.21.2035 Kroll, 1996, Platelets and shear stress, Blood, 88, 1525, 10.1182/blood.V88.5.1525.1525 Holme, 1997, Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis, Arterioscler Thromb Vasc Biol, 17, 646, 10.1161/01.ATV.17.4.646 Maalej, 1998, Effects of shear stress on acute platelet thrombus formation in canine stenosed carotid arteries: an in vivo quantitative study, J Thromb Thrombolysis, 5, 231, 10.1023/A:1008895909921 2002, Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients, BMJ, 324, 71, 10.1136/bmj.324.7329.71 Nakamura, 1998, Platelet adhesion to native type I collagen fibrils. Role of GPVI in divalent cation-dependent and -independent adhesion and thromboxane A2 generation, J Biol Chem, 273, 4338, 10.1074/jbc.273.8.4338 Cipollone, 2002, Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy, Circulation, 106, 399, 10.1161/01.CIR.0000025419.95769.F0 Semb, 2003, Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy, J Am Coll Cardiol, 41, 275, 10.1016/S0735-1097(02)02718-3 Furberg, 1994, Effects of lovastatin on early carotid atherosclerosis and cardiovascular events, Aymptomatic Carotid Artery Progression Study (ACAPS) Research Group, Circulation, 90, 1679, 10.1161/01.CIR.90.4.1679 Smilde, 2001, Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial, Lancet, 357, 577, 10.1016/S0140-6736(00)04053-8 MacMahon, 1998, Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group, Circulation, 97, 1784, 10.1161/01.CIR.97.18.1784 Reid, 2005, The effect of pravastatin on intima media thickness of the carotid artery in patients with normal cholesterol, Eur J Vasc Endovasc Surg, 30, 464, 10.1016/j.ejvs.2005.05.007 Amarenco, 2006, Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) investigators. High-dose atorvastatin after stroke or transient ischemic attack, N Engl J Med, 355, 549, 10.1056/NEJMoa061894 2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3